owensilcox, Author at European Medical Journal - Page 2 of 26

31 Mar 2026

The Role of Muscle in SMA

This interactive infographic explains the role of muscle and motor neurons in the trajectory of spinal muscular atrophy, and considers…

Portable Spacer Solutions for Respiratory Care

In this short on demand video, Alan Kaplan and Job F.M. VanBoven discuss the AeroChamber2go* spacer and the potential benefits to the…

EMJ’s Latest Flagship Journal

Inside, discover how predictive models are reshaping risk prediction and disease surveillance, examine emerging evidence linking air…

ImmunoWELL JCV test: Real-world data

JCV is a DNA polyomavirus and the primary aetiological agent of PML. Most adults carry JCV in its latent form, but the virus can become…

Revisiting Erythroid Response to Luspatercept in the Phase III BELIEVE Trial Using Real-World Response Criteria

Patients with TDT have impaired erythropoiesis and face a chronic treatment burden of regular transfusions and iron chelation therapy to…

Unmet Needs of Children with Mild-to-Moderate Atopic Dermatitis

Study on patient and caregiver experiences of mild-to-moderate atopic dermatitis, revealing unmet needs, emotional burden, and gaps in…

Seborrheic Dermatitis: New Pathophysiology Evidence and Therapeutic Implications

Deepen your proficiency in diagnosing and treating seborrheic dermatitis with recent findings about the science behind this disease…

Biosimilar natalizumab

Experts Simon Thebault and Thomas Berger discuss the impact of biosimilars in MS, in light of the approval of biosimilar-natalizumab…

5 Feb 2026

The first and only approved dual inhibitor of IL-17A and IL-17F1-6

BIMZELX® Demonstrated Deep and Sustained Efficacy to 3 Years Across Multiple Disease Domains of PsA and the Full axSpA Spectrum…

23 Jan 2026

Targeting Endothelin and Angiotensin in IgA Nephropathy

Endothelin-1 (ET-1) and angiotensin II (Ang II) overexpression is recognised as a mediator of disease progression in immunoglobulin…